Company identity
Company number SC384375
Company profile
UK company SC384375, incorporated on 27 August 2010.
Askbio UK Ltd is a UK company with status active founded in 2010 based in Scotland.
Company number SC384375
Updated 07 Jul 2026 09:49
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
1 Mar 2018 to 31 Mar 2020
Production of biopharmaceuticals that are toxic or have detrimental effects on the growth of the host cell line is very challenging. To overcome this challenge researchers have developed a number of promoters allowing control of protein expression during the bioproduction process. The primary aim of that research was to enable a 2-step bioprocessing platf...
1 Jul 2016 to 30 Jun 2019
Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a low cost. This project seek...
1 Aug 2014 to 31 Oct 2015
The bioscience industry currently relies on a small number of organisms to produce the majority of the recombinant products on the market. A collaboration between two UK synthetic biology Synthace and Synpromics and University College London, this project combines cutting edge computational techniques with multifactorial experimental design to develop a n...
1 Jul 2014 to 31 Dec 2015
The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromics's proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and t...
1 Jun 2014 to 30 Nov 2015
The collaboration between Synpromics and Ingenza is focused on developing proprietary protein production systems in engineered yeast strains that improve on currently available alternatives by incorporating novel synthetic promoter constructs rationally designed to drive optimal gene expression. The enabling technology that the project aims to deliver wil...
1 Oct 2013 to 30 Sep 2015
Enhancing methods of protein expression is fundamentally important to new drug development and the efficient production of biopharmaceuticals. The consortium aims to develop a novel means of designing and constructing synthetic promoters that can be employed on an industrial scale to drive the expression of proteins for commercial applications. This will ...
1 Aug 2012 to 31 Oct 2014
The project will deliver new tools that can be used to test potential new drugs, food constituents with possible health benefit, and which also offer a new approach to measuring the effect on human health of particles present in our domestic or workplace environment. These tools will be based upon living cells that are placed in situations where they repr...